FY2025 Earnings Forecast for Amarin Issued By Zacks Research

Amarin Co. plc (NASDAQ:AMRN - Free Report) - Investment analysts at Zacks Research decreased their FY2025 EPS estimates for shares of Amarin in a report issued on Tuesday, February 11th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn ($0.34) per share for the year, down from their previous forecast of ($0.33). The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q4 2025 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.10) EPS.

Separately, StockNews.com raised shares of Amarin from a "sell" rating to a "hold" rating in a research report on Tuesday, February 11th.

Amarin Trading Down 0.8 %

NASDAQ:AMRN traded down $0.01 during trading hours on Friday, hitting $0.61. The stock had a trading volume of 958,760 shares, compared to its average volume of 1,161,960. Amarin has a 1-year low of $0.43 and a 1-year high of $1.36. The business has a 50 day simple moving average of $0.53 and a two-hundred day simple moving average of $0.56. The company has a market cap of $249.36 million, a PE ratio of -6.75 and a beta of 1.83.

Institutional Trading of Amarin

A number of hedge funds have recently made changes to their positions in AMRN. Arkfeld Wealth Strategies L.L.C. lifted its stake in Amarin by 52.6% in the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 20,000 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Amarin during the fourth quarter valued at about $36,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Amarin by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company's stock valued at $48,000 after purchasing an additional 29,992 shares in the last quarter. Generation Capital Management LLC bought a new stake in shares of Amarin during the fourth quarter valued at about $50,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Amarin during the fourth quarter valued at about $55,000. Institutional investors and hedge funds own 22.25% of the company's stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.